Dibdiakova et al. demonstrated that elevated MMP-9 levels were predictive of an aggressive GBM phenotype and correlated with resistance to conventional therapies, indicating that MMP-9 is a relevant therapeutic target not only in halting tumor progression but also in potentially sensitizing tumors to existing treatments. This evidence concerns the gene MMP9 and neoplasm.